Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.